Additionally, innovative codelivery approaches have been developed, such as DTX/ARV‐lip systems that coencapsulate BRD4–PROTAC ARV825 with docetaxel, demonstrating enhanced antitumor effects through dual mechanisms of protein degradation and chemotherapy with tumor inhibition rates reaching 57.4% [408]. The gene discussed is BRD4; the disease is neoplasm.